Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Kalergis, Alexis M ^a,b   Iruretagoyena, Mirentxu I ^a,b   Barrientos, Magaly J ^a   González, Pablo A ^a   Herrada, Andres A ^a   Leiva, Eduardo D ^a   Gutiérrez, Miguel A ^b   Riedel, Claudia A ^c   Bueno, Susan M ^a   Jacobelli, Sergio H ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Andrographolide; Autoimmunity; Dendritic cells; Nuclear factor B; Rosiglitazone; Systemic lupus erythematosus

Indexed keywords

ANDROGRAPHOLIDE; ANTINUCLEAR ANTIBODY; FC RECEPTOR IIB; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE PREDISPOSITION; FEMALE; GLOMERULONEPHRITIS; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DENDRITIC CELLS; DITERPENES; FEMALE; GLOMERULONEPHRITIS; HYPOGLYCEMIC AGENTS; I-KAPPA B PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; RECEPTORS, IGG; THIAZOLIDINEDIONES;

EID: 68249133740     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02964.x     Document Type: Article

References (46)

1. Croker JA, Kimberly RP. SLE: challenges and candidates in human disease. Trends Immunol 2005 26 : 580 6.
2. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005 201 : 703 11.
3. Hahn BH. Antibodies to DNA. N Engl J Med 1998 338 : 1359 68.
4. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003 56 : 481 90.
5. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008 358 : 929 39.
6. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev 2005 5 : 296 306. (Pubitemid 40516155)
7. Jung S. Good, bad and beautiful - the role of dendritic cells in autoimmunity. Autoimmun Rev 2004 3 : 54 60.
8. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001 106 : 263 6.
9. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004 20 : 539 50.
10. Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol 2006 177 : 5878 89.
11. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002 16 : 257 70.
12. Saccani S, Pantano S, Natoli G. Modulation of NF-kappaB activity by exchange of dimers. Mol cell 2003 11 : 1563 74.
13. Zanetti M, Castiglioni P, Schoenberger S, Gerloni M. The role of relB in regulating the adaptive immune response. Ann NY Acad Sci 2003 987 : 249 57.
14. Tan PH, Sagoo P, Chan C et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005 174 : 7633 44.
15. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004 18 : 2195 224.
16. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev 2005 5 : 435 45.
17. Iruretagoyena MI, Sepulveda SE, Lezana JP, Hermoso M, Bronfman M, Gutierrez MA, Jacobelli SH, Kalergis AM. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2006 318 : 59 67.
18. O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 2002 168 : 5491 8.
19. Iruretagoyena MI, Tobar JA, Gonzalez PA, Sepulveda SE, Figueroa CA, Burgos RA, Hancke JL, Kalergis AM. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther 2005 312 : 366 72.
20. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000 13 : 277 85.
21. Handa SS, Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. Indian J Med Res 1990 92 : 276 83.
22. Bueno SM, Gonzalez PA, Carreno LJ, Tobar JA, Mora GC, Pereda CJ, Salazar-Onfray F, Kalergis AM. The capacity of Salmonella to survive inside dendritic cells and prevent antigen presentation to T cells is host specific. Immunology 2008 124 : 522 33.
23. Gonzalez PA, Carreno LJ, Coombs D, Mora JE, Palmieri E, Goldstein B, Nathenson SG, Kalergis AM. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci USA 2005 102 : 4824 9.
24. Herrada AA, Contreras FJ, Tobar JA, Pacheco R, Kalergis AM. Immune complex-induced enhancement of bacterial antigen presentation requires Fcgamma receptor III expression on dendritic cells. Proc Natl Acad Sci USA 2007 104 : 13402 7.
25. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000 192 : 1213 22.
26. Banki Z, Kacani L, Mullauer B et al. Cross-linking of CD32 induces maturation of human monocyte-derived dendritic cells via NF-kappa B signaling pathway. J Immunol 2003 170 : 3963 70.
27. Feinstein DL, Galea E, Gavrilyuk V et al. Peroxisome proliferator- activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002 51 : 694 702.
28. Xia YF, Ye BQ, Li YD et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004 173 : 4207 17.
29. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004 5 : 104 12.
30. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
31. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003 21 : 685 711.
32. Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003 36 : 463 72.
33. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003 171 : 3296 302.
34. Decker P, Kotter I, Klein R, Berner B, Rammensee HG. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford, England) 2006 45 : 1087 95.
35. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006 441 : 431 6.
36. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 2003 3 : 147 58.
37. Gabrielian ES, Shukarian AK, Goukasova GI, Chandanian GL, Panossian AG, Wikman G, Wagner H. A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis. Phytomedicine 2002 9 : 589 97.
38. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003 144 : 2201 7.
39. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004 89 : 2728 35.
40. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka MT. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005 175 : 4948 55.
41. Setoguchi K, Misaki Y, Terauchi Y, Yamauchi T, Kawahata K, Kadowaki T, Yamamoto K. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 2001 108 : 1667 75.
42. O'Dea EL, Barken D, Peralta RQ, Tran KT, Werner SL, Kearns JD, Levchenko A, Hoffmann A. A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity. Mol Syst Biol 2007 3 : 111.
43. Mathes E, O'Dea EL, Hoffmann A, Ghosh G. NF-kappaB dictates the degradation pathway of IkappaBalpha. EMBO J 2008 27 : 1357 67.
44. Ma L, Qian S, Liang X et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 2003 52 : 1976 85.
45. Saemann MD, Kelemen P, Bohmig GA, Horl WH, Zlabinger GJ. Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin inhibition. Am J Transplant 2004 4 : 1448 58.
46. Tomasoni S, Aiello S, Cassis L et al. Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. Transplantation 2005 79 : 1056 61.